Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Targeting cancer cells by synthetic lethality: autophagy and VHL in cancer therapeutics.

Chan DA, Giaccia AJ.

Cell Cycle. 2008 Oct;7(19):2987-90. Epub 2008 Oct 12. Review.

PMID:
18818511
2.

The concept of synthetic lethality in the context of anticancer therapy.

Kaelin WG Jr.

Nat Rev Cancer. 2005 Sep;5(9):689-98. Review.

PMID:
16110319
3.

Autophagy and cell death to target cancer cells: exploiting synthetic lethality as cancer therapies.

Reyjal J, Cormier K, Turcotte S.

Adv Exp Med Biol. 2014;772:167-88. doi: 10.1007/978-1-4614-5915-6_8. Review.

PMID:
24272359
4.

The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.

Kaelin WG.

Cold Spring Harb Symp Quant Biol. 2005;70:159-66. Review.

PMID:
16869749
5.

Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets.

Mizuarai S, Irie H, Schmatz DM, Kotani H.

Curr Mol Med. 2008 Dec;8(8):774-83. Review.

PMID:
19075675
6.

Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics.

Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L, Coleman J, Toro J, Glenn G, Vocke C, Zbar B, Schmidt LS, Bottaro D, Neckers L.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):671s-679s. Review.

7.

The von Hippel-Lindau tumor suppressor gene and kidney cancer.

Kaelin WG Jr.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6290S-5S. Review.

8.

Von Hippel-Lindau disease and endocrine tumour susceptibility.

Woodward ER, Maher ER.

Endocr Relat Cancer. 2006 Jun;13(2):415-25. Review.

9.

The von Hippel-Lindau tumor suppressor gene.

Kondo K, Kaelin WG Jr.

Exp Cell Res. 2001 Mar 10;264(1):117-25. Review.

PMID:
11237528
10.

Von Hippel-Lindau disease.

Kaelin WG.

Annu Rev Pathol. 2007;2:145-73. Review.

PMID:
18039096
11.

The von hippel-lindau tumor suppressor protein: an update.

Kaelin WG Jr.

Methods Enzymol. 2007;435:371-83. Review.

PMID:
17998064
12.

Targeting tumor suppressor genes for cancer therapy.

Liu Y, Hu X, Han C, Wang L, Zhang X, He X, Lu X.

Bioessays. 2015 Dec;37(12):1277-86. doi: 10.1002/bies.201500093. Epub 2015 Oct 7. Review.

PMID:
26445307
13.

Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review.

Chan CC, Collins AB, Chew EY.

Retina. 2007 Jan;27(1):1-7. Review.

14.

The von Hippel-Lindau gene: turning discovery into therapy.

Clark PE, Cookson MS.

Cancer. 2008 Oct 1;113(7 Suppl):1768-78. doi: 10.1002/cncr.23645. Review.

15.

Von hippel-lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development.

Kuehn EW, Walz G, Benzing T.

Cancer Res. 2007 May 15;67(10):4537-40. Review.

16.

Harnessing synthetic lethal interactions in anticancer drug discovery.

Chan DA, Giaccia AJ.

Nat Rev Drug Discov. 2011 May;10(5):351-64. doi: 10.1038/nrd3374. Review.

17.

Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs.

Jackson RA, Chen ES.

Pharmacol Ther. 2016 Jun;162:69-85. doi: 10.1016/j.pharmthera.2016.01.014. Epub 2016 Jan 22. Review.

PMID:
26803999
18.

Synthetic lethality: general principles, utility and detection using genetic screens in human cells.

Nijman SM.

FEBS Lett. 2011 Jan 3;585(1):1-6. doi: 10.1016/j.febslet.2010.11.024. Epub 2010 Nov 19. Review.

19.

Drugging the addict: non-oncogene addiction as a target for cancer therapy.

Nagel R, Semenova EA, Berns A.

EMBO Rep. 2016 Nov;17(11):1516-1531. Epub 2016 Oct 4. Review.

20.

Synthetic lethality and cancer.

O'Neil NJ, Bailey ML, Hieter P.

Nat Rev Genet. 2017 Jun 26. doi: 10.1038/nrg.2017.47. [Epub ahead of print] Review.

PMID:
28649135

Supplemental Content

Support Center